<DOC>
	<DOCNO>NCT00412061</DOCNO>
	<brief_summary>The purpose study evaluate whether everolimus 10 mg / day add treatment depot octreotide prolongs progression free survival compare treatment octreotide alone patient advanced carcinoid tumor .</brief_summary>
	<brief_title>Everolimus Octreotide Patients With Advanced Carcinoid Tumor</brief_title>
	<detailed_description />
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Malignant Carcinoid Syndrome</mesh_term>
	<mesh_term>Serotonin Syndrome</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Inclusion criterion : Advanced ( unresectable metastatic ) carcinoid tumor Confirmed lowgrade intermediategrade neuroendocrine carcinoma Documented progression disease within 12 month prior randomization . Measurable disease determine triphasic computer tomography ( CT ) scan magnetic resonance imaging ( MRI ) . Exclusion criterion : Poorly differentiate neuroendocrine carcinoma , highgrade neuroendocrine carcinoma , adenocarcinoid , goblet cell carcinoma , small cell carcinoma . Hepatic artery embolization within last 6 month cryoablation hepatic metastasis within 2 month enrollment . Previous treatment mammalian target rapamycin ( mTOR ) inhibitor ( sirolimus , temsirolimus , everolimus ) Intolerance hypersensitivity octreotide , everolimus , rapamycins . Severe uncontrolled medical condition Chronic treatment corticosteroid immunosuppressive agent . Other primary cancer within 3 year . Other protocoldefined inclusion/exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Carcinoid</keyword>
	<keyword>Tumor</keyword>
	<keyword>Neuroendocrine</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Octreotide</keyword>
</DOC>